

Table 1 Treatment characteristics

Variable	Result (n/N (%))
RT^a	71/87 (81.6%)
Hypofractionation	14/71 (19.7%)
Conventional fractionation	55/71 (77.5%)
Hyperfractionation	1/71 (1.4%)
Other scheme ^b	1/71 (1.4%)
CT^c	51/87 (59.3%)
Cytotoxic therapy	30/51 (58.8%)
Targeted therapy	17/51 (33.3%)
Cytotoxic + targeted therapy	4/51 (7.9%)
RT vs CT	
Only RT	22/73 (30.1%)
RT + CT	49/73 (67.1%)
Only CT	2/73 (2.7%)
Type targeted therapy	
mTOR-inhibitor	15/21 (71.4%)
Other	6/21 (28.6%)
Re-RT	7/71 (9.9%)
Inclusion in clinical trial^d	11/52 (21.2%)

RT radiotherapy, CT chemotherapy, Re-RT reirradiation, mTOR mammalian target of rapamycin

^a Hypofractionation: 39 Gy in 3 Gy fractions, conventional fractionation: 54-59.4 Gy in 1.8 Gy fractions, hyperfractionation: 66-78 Gy in 1-1.26 Gy fractions

^b 45 Gy – number of fractions unknown

^c Any cytotoxic and/or targeted therapy

^d patients diagnosed from 2010 onwards (no clinical trials available in Europe before 2010)